Supporting this hypothesis, inhibition of factors involved in therapy‐induced DNA damage response (DDR), like CHK1 activation by ATR inhibitors, results in EMT and ZEB1 upregulation in CRC cells, reduced phosphorylation of CHK1 and decreased sensitivity to ATR inhibition (Song et al, 2018; Zhang et al, 2018). This evidence concerns the gene ZEB1 and colorectal carcinoma.